GLP1R and endothelial dysfunction: This may be due to the increase in GLP-1 levels by incretin analogs (such as liraglutide) rather than due to incretin enhancers (such as DPP-4is), and the positive effects of GLP-1 on endothelial dysfunction, inflammation and oxidative stress exceed its positive effects on body weight and blood pressure (109, 110).